Remove DNA Remove Immune Response Remove Research Remove RNA
article thumbnail

Harnessing circRNAs could “change the landscape” of cancer therapy

Drug Discovery World

Circular RNAs (circRNAs) have “remarkable potential” to improve cancer treatment and patient outcomes within the next five to 10 years, according to a new study by Flinders University in Australia. We’ve also discovered that high levels of circRNAs in certain people can cause mutations in their DNA which results in leukaemia.”

RNA 59
article thumbnail

Rome Therapeutics raises $77m for junk DNA-targeting drugs

pharmaphorum

Startup Rome Therapeutics has raised $77 million in second-round financing to help mine sequences of DNA – which were dismissed for years as ‘junk’ – for hidden treasure. Much of this repeatome is thought to derive from viruses that embedded in our DNA millions of years ago.

DNA 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Gene Therapy and Pharmacokinetics

Camargo

It is a comprehensive term which encompasses a large variety of therapy products including viral and bacterial vectors, plasmid DNA, human gene editing technology, and patient-specific cellular gene therapy. For example, it is beneficial to administer RNA treatments for some lung diseases directly to the disease site through inhalation.

article thumbnail

Leading innovators in flavivirus vaccine components

Pharmaceutical Technology

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. The structural proteins include the capsid, pre-membrane/membrane proteins and envelope (E) proteins.

article thumbnail

HIV vaccines suffer setbacks but new approaches could turn the tide

Pharmaceutical Technology

Since HIV integrates with the DNA, eliminating the virus from the body is very difficult, explains David Montefiori, PhD, director of the Laboratory for AIDS Vaccine Research and Development at Duke University in Durham, North Carolina. This response was also seen in the RV 144 trial, she notes.

article thumbnail

Roche pays $200m for Vaccibody’s cancer vaccine drug

pharmaphorum

Vaccibody, which is also entitled to tiered royalties on sales of any marketed products, will develop the DNA-based individualised neoantigen vaccines until the end of phase 1b. Vaccibody has been working on a targeted DNA-based vaccine platform, in a bid to find a potential new treatment paradigm for individualised cancer vaccines.

article thumbnail

World AIDS Day 2023: New and Promising Treatments for HIV/AIDS

XTalks

Over the last 35 years, substantial strides have been made in tackling HIV/AIDS, propelled by advancements in medical research, enhanced accessibility to treatment and prevention and a more comprehensive understanding of the virus. World AIDS Day offers an occasion for reflection on the strides achieved thus far.